Patient-Reported Outcomes Similar With Extended Natalizumab Dosing Interval
NOVA trial looks at 6-week dosing to reduce PML risk
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NOVA trial looks at 6-week dosing to reduce PML risk
General neurologists fall short in their knowledge of key multiple sclerosis diagnostic criteria standards compared with MS experts, new findings show, which may be detrimental to patient management.
Diroximel fumarate led to significant improvements in clinical and radiologic outcomes among young adult patients with multiple sclerosis.
Use of ponesimod in women with multiple sclerosis who are pregnant was not associated with a higher proportion of spontaneous abortions.
Vaccines containing SARS-CoV-2 antigens may lead to enhanced autoimmunity resulting in insidious and extensive inflammation.